Published: May 21, 2021 By Alex Keown
Biopharma and life sciences companies strengthen their leadership teams and board with these Movers & Shakers.
AavantiBio – Jessie Hanrahan was named chief regulatory officer of AavantiBio. Hanrahan will oversee global regulatory affairs for AavantiBio’s diversified pipeline of gene therapy programs targeting rare diseases with significant unmet medical needs. Most recently, she was Vice President of Regulatory Science at bluebird bio, Inc. Prior to bluebird bio, Hanrahan held positions of increasing responsibility at Genzyme Corp. where she worked across the oncology, multiple sclerosis and rare disease therapeutic areas. Earlier in her career, Hanrahan worked at Boston Scientific Corporation.
Share this article
Share this article
NASHVILLE, Tenn., May 4, 2021 /PRNewswire/ Cryoport, Inc. (NASDAQ: CYRX) ( Cryoport or the Company ), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced financial results for the three-month period ended March 31, 2021.
Jerrell Shelton, CEO of Cryoport, said, It was a strong quarter and it developed as we had anticipated. We entered 2021 with an unrivaled leadership position with market-leading temperature-controlled supply chain solutions for the life sciences industry in our markets of Biopharma/Pharma, Animal Health and Reproductive Medicine. Our global platform, consisting of 32 locations and a family of companies that provide mutually reinforcing solutions, services and products, delivered an outstanding performance. Cryoport s revenue grew to a record $53.3 million for the quarter with our recent acquisitions of MVE Biological Solutions and CRYOPDP contributing signif
Cell and gene therapy: The next frontier in pharmaceutical services acs.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from acs.org Daily Mail and Mail on Sunday newspapers.
Scribe and student: For the past five years, Brooke Ford has worked her way through college as an emergency room scribe at a few local hospitals. In her senior year at William & Mary, as the COVID-19 pandemic ravaged the nation, she managed medical scribes at two hospitals. Courtesy photo
Photo - of - by Adrienne Berard | April 16, 2021
For the better part of the past year, Brooke Ford’s return home from work has been an exercise in mitigating the spread of a potentially deadly pathogen.
She pulls off all her personal protective equipment, washes her hands, showers off, changes clothes, throws out any food or drink she may have touched and greets her family.
Dive Brief:
Biotech startup Jaguar Gene Therapy has raised $139 million in new funding from high-profile backers Eli Lilly and ARCH Venture Partners, which joined venture founder Deerfield Management in closing a Series B round announced Tuesday.
The fundraising comes less than two months after Jaguar s official unveiling in late February with a slate of preclinical gene therapies targeting an inherited metabolic disorder called galactosemia as well as gene-linked autism and Type 1 diabetes.
Jaguar said it would use the cash infusion to advance its pipeline, and expects to begin the preclinical studies that are needed to support human testing in the second half of this year. Jaguar is led Joe Nolan and Sean Nolan (unrelated), two former executives at AveXis, the biotech developer of Zolgensma that s now owned by Novartis.